EBC-46 Regulatory Landscape 2026: Stelfonta Approvals and DSHEA Framework
How tigilanol tiglate is regulated across jurisdictions — from FDA veterinary approval of Stelfonta to DSHEA's established framework for botanical dietary supplements.
Regulatory frameworks governing tigilanol tiglate span multiple jurisdictions and product categories, reflecting the compound's dual identity: as a pharmaceutical active ingredient in veterinary medicine and as a constituent of botanical dietary supplements. Understanding how these frameworks differ is essential for anyone researching EBC-46.
Stelfonta: The Pharmaceutical Pathway
Tigilanol tiglate achieved its first pharmaceutical approval as Stelfonta, a veterinary injectable developed by QBiotics Group for the treatment of non-metastatic mast cell tumours in dogs. The FDA granted approval for Stelfonta following rigorous Phase I–III clinical trials demonstrating a high complete response rate in canine subjects. Approval by the EMA followed, extending its use in European veterinary practice.
Stelfonta is administered by veterinary professionals as a single intratumoral injection. It is not available for human purchase or use. The pharmaceutical approval process for veterinary drugs requires demonstrated safety, efficacy, and manufacturing consistency — a standard that takes years and substantial investment to achieve.
DSHEA: The Established Framework for Botanical Supplements
In the United States, dietary supplements including botanical extracts are regulated under the Dietary Supplement Health Education Act (DSHEA) of 1994. DSHEA is an established, legitimate legal framework — not a regulatory grey zone. Under DSHEA, manufacturers are responsible for ensuring product safety before marketing, and the FDA has authority to take action against unsafe products. Supplements may not make therapeutic claims but may carry structure/function claims describing how an ingredient affects normal body function.
Blushwood berry extract supplements sold in the US fall under this framework. Responsible brands carry the required FDA disclaimer: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease." This is standard practice across the botanical supplement category.
Australian TGA Considerations
The Therapeutic Goods Administration (TGA) regulates therapeutic goods in Australia. Suppliers making no therapeutic claims and marketing products purely as dietary supplements operate outside TGA jurisdiction. Blushwood Health explicitly makes no therapeutic claims about its products.
What This Means for Buyers
Buyers should understand that a dietary supplement containing blushwood berry extract is a different product category from pharmaceutical tigilanol tiglate. Supplements are not required to complete clinical trials before sale. What distinguishes quality brands is voluntary commitment to third-party testing, GMP manufacturing, and transparent labelling — standards that reputable suppliers like Blushwood Health meet through Eurofins batch testing and GMP-certified manufacturing.
References
1. FDA — Stelfonta Approval Notice, 2020.
2. US FDA — Dietary Supplement Guidance, current.
3. QBiotics Group — Tigilanol Tiglate, clinical pathway summary.
Related Articles
See also: Complete Guide to EBC-46 and Tigilanol Tiglate and Blushwood Berry Extract as a Natural EBC-46 Supplement.
